safety and tolerability and to determine the optimal dose of ADRX-0706. The company expects an initial data readout in mid-2024. About ADRX-0706: ADRX-0706 is a fully proprietary ADC product candidate discovered by Adcentrx. The antibody component...
Australia: MedReleaf Australia is a subsidiary company of Aurora Cannabis Inc., established in 2016 and acquired in 2024. MedReleaf is licensed by the Australian Federal Government's Office of Drug Control (ODC) to cultivate and manufacture medical...
also coincides with the company’s announcement of a new expanded minimum temperature of -40°C (-40°F), available in summer 2024. About CBX: CBX has been a leading provider of active temperature-controlled solutions for ground transportation of...
Therapy. Factor will deliver seven presentations, representing the company's most expansive presentation of data to date. "2024 marks the fifth year that Factor will present our latest data at the Annual Meeting of the ASGCT," said Dr. Matt Angel,...
our efforts to present topline efficacy readouts and an in-depth safety analysis following study conclusion in Q4 2024." About AP-325: AP-325 is a unique small molecule designed to act as a positive allosteric modulator of the GABAA receptor in the...
groundbreaking vector technology designed to revolutionize viral vector production. With the official launch on March 20, 2024, ProteoNic extends a warm invitation to CDMOs, biotechs, and biopharmaceutical companies to experience firsthand the...
therapeutics to address oncogenic and immune dysregulation that drive cancer, announced three poster presentations at the 2024 American Association for Cancer Research (AACR). Sapience will present non-clinical immunotherapy results at AACR from...
announced that its Quantra Hemostasis System with QPlus® and QStat® Cartridges has been named a finalist in the 2024 Edison™ Awards. The company was honored in the health, medical, and biotechnology category for its Quantra Hemostasis System. The...
the endless possibilities of the endocannabinoid system, we are now ready to finalize TPT0701 for pre-clinical testing in 2024". "Compounds, such as TPT0701, display physicochemical properties that render them difficult to formulate by means of...
Model of Nonalcoholic Steatohepatitis", has published online and will be published in the print edition cover dated March, 2024. Co-author Jeffrey N. Miner Ph.D. , cofounder and CSO of Viscient Biosciences underscored the importance of being able...
